{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:38:46Z","timestamp":1790293126514,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["SQ2024AAA031359"],"award-info":[{"award-number":["SQ2024AAA031359"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovation Platform and Talent Program","award":["2023TP1047"],"award-info":[{"award-number":["2023TP1047"]}]},{"name":"Scientific Research Project of Hunan Provincial Health Commission","award":["202218014518"],"award-info":[{"award-number":["202218014518"]}]},{"name":"Clinical Research 4310 Program of the First Affiliated Hospital of University of South China","award":["20224310NHYCG03"],"award-info":[{"award-number":["20224310NHYCG03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04526-5","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:25:23Z","timestamp":1765808723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Sleep disorders in Parkinson\u2019s disease: evaluating pharmacological treatments through systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jingqi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runtang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6460-3420","authenticated-orcid":false,"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"1:6","key":"4526_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s44400-025-00008-0","volume":"1","author":"E Simmonds","year":"2025","unstructured":"Simmonds E, Levine KS, Han J, Iwaki H, Koretsky MJ, Kuznetsov N, et al. Sleep disturbances as risk factors for neurodegeneration later in life. NPJ Dement. 2025;1(1:6):6. https:\/\/doi.org\/10.1038\/s44400-025-00008-0.","journal-title":"NPJ Dement"},{"key":"4526_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-023-00340-6","author":"Y Shen","year":"2023","unstructured":"Shen Y, Lv QK, Xie WY, Gong SY, Zhuang S, Liu JY, et al. Circadian disruption and sleep disorders in neurodegeneration. Transl Neurodegener. 2023. https:\/\/doi.org\/10.1186\/s40035-023-00340-6.","journal-title":"Transl Neurodegener"},{"issue":"18","key":"4526_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13182898","volume":"13","author":"L Anghel","year":"2023","unstructured":"Anghel L, Ciubar\u0103 A, Nechita A, Nechita L, Manole C, Baroiu L, et al. Sleep disorders associated with neurodegenerative diseases. Diagnostics. 2023;13(18):2898. https:\/\/doi.org\/10.3390\/diagnostics13182898.","journal-title":"Diagnostics"},{"issue":"10357","key":"4526_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/s0140-6736(22)00877-7","volume":"400","author":"N Meyer","year":"2022","unstructured":"Meyer N, Harvey AG, Lockley SW, Dijk DJ. Circadian rhythms and disorders of the timing of sleep. Lancet. 2022;400(10357):1061\u201378. https:\/\/doi.org\/10.1016\/s0140-6736(22)00877-7.","journal-title":"Lancet"},{"issue":"7","key":"4526_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2025.0488","volume":"82","author":"GM Reimann","year":"2025","unstructured":"Reimann GM, Hoseini A, Ko\u00e7ak M, Beste M, K\u00fcppers V, Rosenzweig I, et al. Distinct convergent brain alterations in sleep disorders and sleep deprivation: a meta-analysis. JAMA Psychiatr. 2025;82(7):681\u201391. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0488.","journal-title":"JAMA Psychiatr"},{"key":"4526_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.smrv.2016.10.005","volume":"36","author":"JS Benjamins","year":"2017","unstructured":"Benjamins JS, Migliorati F, Dekker K, Wassing R, Moens S, Blanken TF, et al. Insomnia heterogeneity: characteristics to consider for data-driven multivariate subtyping. Sleep Med Rev. 2017;36:71\u201381. https:\/\/doi.org\/10.1016\/j.smrv.2016.10.005.","journal-title":"Sleep Med Rev"},{"issue":"10357","key":"4526_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/s0140-6736(22)01018-2","volume":"400","author":"L P\u00e9rez-Carbonell","year":"2022","unstructured":"P\u00e9rez-Carbonell L, Mignot E, Leschziner G, Dauvilliers Y. Understanding and approaching excessive daytime sleepiness. Lancet. 2022;400(10357):1033\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(22)01018-2.","journal-title":"Lancet"},{"key":"4526_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-024-06103-5","author":"B Golabi","year":"2024","unstructured":"Golabi B, Razmaray H, Seyedi-Sahebari S, Bandehagh H, Hakimzadeh Z, Khosroshahi A, et al. Sleep and cognitive outcomes in multiple sclerosis; a systematic review. BMC Psychiatry. 2024. https:\/\/doi.org\/10.1186\/s12888-024-06103-5.","journal-title":"BMC Psychiatry"},{"key":"4526_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106219","volume":"93","author":"A Moradi","year":"2025","unstructured":"Moradi A, Ebrahimian A, Sadigh-Eteghad S, Talebi M, Naseri A. Sleep quality in multiple sclerosis: a systematic review and meta-analysis based on Pittsburgh sleep quality index. Mult Scler Relat Disord. 2025;93:106219. https:\/\/doi.org\/10.1016\/j.msard.2024.106219.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"4526_CR10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/14737175.2024.2341004","volume":"24","author":"A Bedward","year":"2024","unstructured":"Bedward A, Kaur J, Seedat S, Donohue H, Kow CS, Rasheed MK, et al. Pharmacological interventions to improve sleep in people with Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials. Expert Rev Neurother. 2024;24(5):527\u201339. https:\/\/doi.org\/10.1080\/14737175.2024.2341004.","journal-title":"Expert Rev Neurother"},{"key":"4526_CR11","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.3233\/jpd-212749","volume":"12 7","author":"L Sch\u00fctz","year":"2022","unstructured":"Sch\u00fctz L, Sixel-D\u00f6ring F, Hermann W. Management of sleep disturbances in parkinson\u2019s disease. J Parkinsons Dis. 2022;12 7:2029\u201358. https:\/\/doi.org\/10.3233\/jpd-212749.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"4526_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.7812\/tpp\/22.114","volume":"27","author":"EE Jaqua","year":"2023","unstructured":"Jaqua EE, Hanna M, Labib W, Moore C, Matossian V. Common sleep disorders affecting older adults. Perm J. 2023;27(1):122\u201332. https:\/\/doi.org\/10.7812\/tpp\/22.114.","journal-title":"Perm J"},{"issue":"9","key":"4526_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/s1474-4422(24)00170-4","volume":"23","author":"A Iranzo","year":"2024","unstructured":"Iranzo A, Cochen De Cock V, Fantini ML, P\u00e9rez-Carbonell L, Trotti LM. Sleep and sleep disorders in people with Parkinson\u2019s disease. Lancet Neurol. 2024;23(9):925\u201337. https:\/\/doi.org\/10.1016\/s1474-4422(24)00170-4.","journal-title":"Lancet Neurol"},{"issue":"10291","key":"4526_CR14","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0140-6736(21)00218-x","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C. Parkinson\u2019s disease. Lancet. 2021;397(10291):2284\u2013303. https:\/\/doi.org\/10.1016\/s0140-6736(21)00218-x.","journal-title":"Lancet"},{"issue":"1","key":"4526_CR15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s13311-013-0236-z","volume":"11","author":"LM Trotti","year":"2014","unstructured":"Trotti LM, Bliwise DL. Treatment of the sleep disorders associated with Parkinson\u2019s disease. Neurotherapeutics. 2014;11(1):68\u201377. https:\/\/doi.org\/10.1007\/s13311-013-0236-z.","journal-title":"Neurotherapeutics"},{"issue":"12","key":"4526_CR16","first-page":"26","volume":"112","author":"IV Litvinenko","year":"2012","unstructured":"Litvinenko IV, Krasakov IV, Tikhomirova OV. Sleep disorders in Parkinson\u2019s disease without dementia: a comparative randomized controlled study of melatonin and clonazepam. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(12):26\u201330.","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova."},{"issue":"2","key":"4526_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mds.27886","volume":"35","author":"M Gilat","year":"2020","unstructured":"Gilat M, Coeytaux Jackson A, Marshall NS, Hammond D, Mullins AE, Hall JM, et al. Melatonin for rapid eye movement sleep behavior disorder in Parkinson\u2019s disease: a randomised controlled trial. Mov Disord. 2020;35(2):344\u20139. https:\/\/doi.org\/10.1002\/mds.27886.","journal-title":"Mov Disord"},{"key":"4526_CR18","first-page":"905","volume":"25 8","author":"B H\u00f6gl","year":"2002","unstructured":"H\u00f6gl B, Saletu M, Brandauer E, Glatzl S, Frauscher B, Seppi K, et al. Modafinil for the treatment of daytime sleepiness in parkinson\u2019s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. 2002;25 8:905\u20139.","journal-title":"Sleep"},{"issue":"4","key":"4526_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/mds.24909","volume":"27","author":"R Di Giacopo","year":"2012","unstructured":"Di Giacopo R, Fasano A, Quaranta D, Marca GD, Bove F, Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson\u2019s disease. Mov Disord. 2012;27(4):559\u201361. https:\/\/doi.org\/10.1002\/mds.24909.","journal-title":"Mov Disord"},{"key":"4526_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.sleep.2021.02.038","volume":"81","author":"A Stefani","year":"2021","unstructured":"Stefani A, Santamaria J, Iranzo A, Hackner H, Schenck CH, H\u00f6gl B. Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson\u2019s disease dementia. Sleep Med. 2021;81:180\u20137. https:\/\/doi.org\/10.1016\/j.sleep.2021.02.038.","journal-title":"Sleep Med"},{"key":"4526_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2016.03.002","volume":"27","author":"TM Rodrigues","year":"2016","unstructured":"Rodrigues TM, Castro Caldas A, Ferreira JJ. Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson\u2019s disease: systematic review and meta-analysis. Parkinsonism Relat Disord. 2016;27:25\u201334. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.03.002.","journal-title":"Parkinsonism Relat Disord"},{"key":"4526_CR22","doi-asserted-by":"publisher","first-page":"592989","DOI":"10.3389\/fnins.2020.592989","volume":"14","author":"Z Yang","year":"2020","unstructured":"Yang Z, Zhang X, Li C, Chi S, Xie A. Molecular mechanisms underlying reciprocal interactions between sleep disorders and parkinson\u2019s disease. FRONT NEUROSCI-SWITZ. 2020;14:592989. https:\/\/doi.org\/10.3389\/fnins.2020.592989.","journal-title":"FRONT NEUROSCI-SWITZ"},{"key":"4526_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13060914","volume":"13","author":"MA Samizadeh","year":"2023","unstructured":"Samizadeh MA, Fallah H, Toomarisahzabi M, Rezaei F, Rahimi-Danesh M, Akhondzadeh S, et al. Parkinson\u2019s disease: a narrative review on potential molecular mechanisms of sleep disturbances, REM behavior disorder, and melatonin. Brain Sci. 2023;13:6:914. https:\/\/doi.org\/10.3390\/brainsci13060914.","journal-title":"Brain Sci"},{"key":"4526_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109420","volume":"64","author":"R Havekes","year":"2019","unstructured":"Havekes R, Heckman PRA, Wams EJ, Stasiukonyte N, Meerlo P, Eisel ULM. Alzheimer\u2019s disease pathogenesis: the role of disturbed sleep in attenuated brain plasticity and neurodegenerative processes. Cell Signal. 2019;64:109420. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109420.","journal-title":"Cell Signal"},{"key":"4526_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01897-y","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ren R, Yang L, Zhang H, Shi Y, Okhravi HR, et al. Sleep in Alzheimer\u2019s disease: a systematic review and meta-analysis of polysomnographic findings. Transl Psychiatry. 2022. https:\/\/doi.org\/10.1038\/s41398-022-01897-y.","journal-title":"Transl Psychiatry"},{"key":"4526_CR26","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4526_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336 7650","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336 7650:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"4526_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/s0140-6736(22)00878-9","volume":"400 10347","author":"F De Crescenzo","year":"2022","unstructured":"De Crescenzo F, D\u2019Al\u00f2 GL, Ostinelli EG, Ciabattini M, Di Franco V, Watanabe N, et al. Comparative effects of Pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022;400 10347:170\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(22)00878-9.","journal-title":"Lancet"},{"issue":"8","key":"4526_CR29","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1212\/01.Wnl.0000158652.74601.48","volume":"64","author":"CL Comella","year":"2005","unstructured":"Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime Pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005;64(8):1450\u20131. https:\/\/doi.org\/10.1212\/01.Wnl.0000158652.74601.48.","journal-title":"Neurology"},{"issue":"7","key":"4526_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.parkreldis.2013.03.003","volume":"19","author":"S Rios Romenets","year":"2013","unstructured":"Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson\u2019s disease - A randomized study. Parkinsonism Relat Disord. 2013;19(7):670\u20135. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.03.003.","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"4526_CR31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s11325-021-02417-w","volume":"26","author":"M Meloni","year":"2022","unstructured":"Meloni M, Figorilli M, Carta M, Tamburrino L, Cannas A, Sanna F. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson\u2019s disease. Sleep Breath. 2022;26(3):1023\u201331. https:\/\/doi.org\/10.1007\/s11325-021-02417-w.","journal-title":"Sleep Breath"},{"key":"4526_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100285","volume":"11","author":"H Kataoka","year":"2024","unstructured":"Kataoka H, Isogawa M, Nanaura H, Kurakami H, Hasebe M, Kinugawa K, et al. Effect of zonisamide on sleep and rapid eye movement sleep behavioral disorders in patients with Parkinson\u2019s disease: a randomized control trial. Clinical Parkinsonism & Related Disorders. 2024;11:100285. https:\/\/doi.org\/10.1016\/j.prdoa.2024.100285.","journal-title":"Clinical Parkinsonism & Related Disorders"},{"key":"4526_CR33","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.sleep.2024.10.020","volume":"124","author":"R Sugumaran","year":"2024","unstructured":"Sugumaran R, Sai Krishna KS, Saibaba J, Narayan SK, Sandhiya S, Rajeswari M. Melatonin on sleep in Parkinson\u2019s disease: a randomized double blind placebo controlled trial. Sleep Med. 2024;124:502\u20139. https:\/\/doi.org\/10.1016\/j.sleep.2024.10.020.","journal-title":"Sleep Med"},{"key":"4526_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2020.03.029","volume":"75","author":"JH Ahn","year":"2020","unstructured":"Ahn JH, Kim M, Park S, Jang W, Park J, Oh E, et al. Prolonged-release melatonin in Parkinson\u2019s disease patients with a poor sleep quality: a randomized trial. Parkinsonism Relat Disord. 2020;75:50\u20134. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.03.029.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"4526_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8546-8-14","volume":"8","author":"W Pan","year":"2013","unstructured":"Pan W, Kwak S, Li G, Chen Y, Cai D. Therapeutic effect of Yang-Xue-Qing-Nao granules on sleep dysfunction in Parkinson\u2019s disease. Chin Med. 2013;8(1):14. https:\/\/doi.org\/10.1186\/1749-8546-8-14.","journal-title":"Chin Med"},{"issue":"3","key":"4526_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/mds.10390","volume":"18","author":"CH Adler","year":"2003","unstructured":"Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson\u2019s disease. Mov Disord. 2003;18(3):287\u201393. https:\/\/doi.org\/10.1002\/mds.10390.","journal-title":"Mov Disord"},{"key":"4526_CR37","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/jnnp.2005.065870","volume":"76 12","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in parkinson\u2019s disease: double blind, placebo controlled parallel trial. J NEUROL NEUROSUR PS. 2005;76 12:1636\u20139. https:\/\/doi.org\/10.1136\/jnnp.2005.065870.","journal-title":"J NEUROL NEUROSUR PS"},{"issue":"1","key":"4526_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40120-021-00246-3","volume":"10","author":"SH Mehta","year":"2021","unstructured":"Mehta SH, Pahwa R, Tanner CM, Hauser RA, Johnson R. Effects of Gocovri (amantadine) extended release capsules on non-motor symptoms in patients with Parkinson\u2019s disease and dyskinesia. NEUROL THER. 2021;10(1):307\u201320. https:\/\/doi.org\/10.1007\/s40120-021-00246-3.","journal-title":"NEUROL THER"},{"issue":"1","key":"4526_CR39","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1001\/jamaneurol.2017.3171","volume":"75","author":"F B\u00fcchele","year":"2018","unstructured":"B\u00fcchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, et al. Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75(1):114\u20138. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3171.","journal-title":"JAMA Neurol"},{"issue":"10","key":"4526_CR40","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1002\/mds.28702","volume":"36","author":"A Videnovic","year":"2021","unstructured":"Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, et al. Solriamfetol for excessive daytime sleepiness in Parkinson\u2019s disease: phase 2 proof-of-concept trial. Mov Disord. 2021;36(10):2408\u201312. https:\/\/doi.org\/10.1002\/mds.28702.","journal-title":"Mov Disord"},{"issue":"5","key":"4526_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S1474-4422(22)00085-0","volume":"21","author":"VC De Cock","year":"2022","unstructured":"De Cock VC, Dodet P, Leu-Semenescu S, Aerts C, Castelnovo G, Abril B, et al. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson\u2019s disease (APOMORPHEE): a multicentre, randomised, controlled, double-blind crossover study. Lancet Neurol. 2022;21(5):428\u201337. https:\/\/doi.org\/10.1016\/S1474-4422(22)00085-0.","journal-title":"Lancet Neurol"},{"issue":"11","key":"4526_CR42","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1002\/mds.23168","volume":"25","author":"M Menza","year":"2010","unstructured":"Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, et al. Treatment of insomnia in Parkinson\u2019s disease: a controlled trial of Eszopiclone and placebo. Mov Disord. 2010;25(11):1708\u201314. https:\/\/doi.org\/10.1002\/mds.23168.","journal-title":"Mov Disord"},{"key":"4526_CR43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.sleep.2016.01.016","volume":"21","author":"M Pierantozzi","year":"2016","unstructured":"Pierantozzi M, Placidi F, Liguori C, Albanese M, Imbriani P, Marciani MG, et al. Rotigotine may improve sleep architecture in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Med. 2016;21:140\u20134. https:\/\/doi.org\/10.1016\/j.sleep.2016.01.016.","journal-title":"Sleep Med"},{"issue":"7","key":"4526_CR44","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.28577","volume":"36","author":"CMO de Almeida","year":"2021","unstructured":"de Almeida CMO, Brito MMC, Bosaipo NB, Pimentel AV, Tumas V, Zuardi AW, et al. Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord. 2021;36(7):1711\u20135. https:\/\/doi.org\/10.1002\/mds.28577.","journal-title":"Mov Disord"},{"key":"4526_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jns.2019.04.029","volume":"401","author":"C Shin","year":"2019","unstructured":"Shin C, Park H, Lee WW, Kim HJ, Kim HJ, Jeon B. Clonazepam for probable REM sleep behavior disorder in Parkinson\u2019s disease: a randomized placebo-controlled trial. J Neurol Sci. 2019;401:81\u20136. https:\/\/doi.org\/10.1016\/j.jns.2019.04.029.","journal-title":"J Neurol Sci"},{"issue":"7","key":"4526_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","volume":"79","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M. Caffeine for treatment of Parkinson disease. Neurology. 2012;79(7):651\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e318263570d.","journal-title":"Neurology"},{"key":"4526_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.sleep.2005.04.004","volume":"6 5","author":"GA Dowling","year":"2005","unstructured":"Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson\u2019s disease. Sleep Med. 2005;6 5:459\u201366. https:\/\/doi.org\/10.1016\/j.sleep.2005.04.004.","journal-title":"Sleep Med"},{"issue":"5","key":"4526_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","volume":"72","author":"CJ Loland","year":"2012","unstructured":"Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S. R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry. 2012;72(5):405\u201313. https:\/\/doi.org\/10.1016\/j.biopsych.2012.03.022.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"4526_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/ejn.13376","volume":"45","author":"M Mereu","year":"2017","unstructured":"Mereu M, Chun LE, Prisinzano TE, Newman AH, Katz JL, Tanda G. The unique psychostimulant profile of (\u00b1)-modafinil: investigation of behavioral and neurochemical effects in mice. Eur J Neurosci. 2017;45(1):167\u201374. https:\/\/doi.org\/10.1111\/ejn.13376.","journal-title":"Eur J Neurosci"},{"issue":"9","key":"4526_CR50","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41386-020-0680-5","volume":"45","author":"M Mereu","year":"2020","unstructured":"Mereu M, Hiranita T, Jordan CJ, Chun LE, Lopez JP, Coggiano MA, et al. Modafinil potentiates cocaine self-administration by a dopamine-independent mechanism: possible involvement of gap junctions. Neuropsychopharmacology. 2020;45(9):1518\u201326. https:\/\/doi.org\/10.1038\/s41386-020-0680-5.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"4526_CR51","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/sj.npp.1301534","volume":"33","author":"MJ Minzenberg","year":"2008","unstructured":"Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology. 2008;33(7):1477\u2013502. https:\/\/doi.org\/10.1038\/sj.npp.1301534.","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"4526_CR52","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00213-020-05691-w","volume":"238","author":"D Repantis","year":"2021","unstructured":"Repantis D, Bovy L, Ohla K, K\u00fchn S, Dresler M. Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine. Psychopharmacology. 2021;238(2):441\u201351. https:\/\/doi.org\/10.1007\/s00213-020-05691-w.","journal-title":"Psychopharmacology"},{"key":"4526_CR53","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1310\/hpj4907-612","volume":"49 7","author":"JA Generali","year":"2014","unstructured":"Generali JA, Cada DJ, Modafinil. Parkinson disease-related somnolence. Hosp Pharm. 2014;49 7:612\u20134. https:\/\/doi.org\/10.1310\/hpj4907-612.","journal-title":"Hosp Pharm"},{"issue":"10","key":"4526_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046599","volume":"7","author":"M Raineri","year":"2012","unstructured":"Raineri M, Gonzalez B, Goitia B, Garcia-Rill E, Krasnova IN, Cadet JL, et al. Modafinil abrogates methamphetamine-induced neuroinflammation and apoptotic effects in the mouse striatum. PLoS One. 2012;7(10):e46599. https:\/\/doi.org\/10.1371\/journal.pone.0046599.","journal-title":"PLoS One"},{"issue":"2","key":"4526_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mds.20308","volume":"20","author":"NJ Diederich","year":"2005","unstructured":"Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson\u2019s disease as disturbed external\/internal perceptions: focused review and a new integrative model. Mov Disorders: Official J Mov Disorder Soc. 2005;20(2):130\u201340. https:\/\/doi.org\/10.1002\/mds.20308.","journal-title":"Mov Disorders: Official J Mov Disorder Soc"},{"issue":"3","key":"4526_CR56","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5664\/jcsm.10374","volume":"19","author":"N Vincent","year":"2023","unstructured":"Vincent N, Dirkse D, Giannouli E, McQuarrie A. Transdiagnostic cognitive behavioral therapy for nightmares and parasomnias. J Clin Sleep Med. 2023;19(3):499\u2013509. https:\/\/doi.org\/10.5664\/jcsm.10374.","journal-title":"J Clin Sleep Med"},{"key":"4526_CR57","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ajps.2017.11.004","volume":"13 6","author":"N Borkar","year":"2018","unstructured":"Borkar N, Mu H, Holm R. Challenges and trends in apomorphine drug delivery systems for the treatment of Parkinson\u2019s disease. Asian J Pharm Sci. 2018;13 6:507\u201317. https:\/\/doi.org\/10.1016\/j.ajps.2017.11.004.","journal-title":"Asian J Pharm Sci"},{"issue":"9","key":"4526_CR58","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905\u201318. https:\/\/doi.org\/10.1007\/s40263-019-00661-z.","journal-title":"CNS Drugs"},{"issue":"1:310","key":"4526_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02614-z","volume":"13","author":"D Yao","year":"2023","unstructured":"Yao D, Li R, Hao J, Huang H, Wang X, Ran L, et al. Melatonin alleviates depression-like behaviors and cognitive dysfunction in mice by regulating the circadian rhythm of AQP4 polarization. Transl Psychiatry. 2023;13(1:310):310. https:\/\/doi.org\/10.1038\/s41398-023-02614-z.","journal-title":"Transl Psychiatry"},{"issue":"2","key":"4526_CR60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/s0165-6147(00)88978-6","volume":"16","author":"ML Dubocovich","year":"1995","unstructured":"Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995;16(2):50\u20136. https:\/\/doi.org\/10.1016\/s0165-6147(00)88978-6.","journal-title":"Trends Pharmacol Sci"},{"issue":"13","key":"4526_CR61","doi-asserted-by":"publisher","first-page":"6133","DOI":"10.1073\/pnas.91.13.6133","volume":"91","author":"T Ebisawa","year":"1994","unstructured":"Ebisawa T, Karne S, Lerner MR, Reppert SM. Expression cloning of a high-affinity melatonin receptor from xenopus dermal melanophores. Proc Natl Acad Sci USA. 1994;91(13):6133\u20137. https:\/\/doi.org\/10.1073\/pnas.91.13.6133.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 5","key":"4526_CR62","first-page":"19","volume":"57","author":"M Karasek","year":"2006","unstructured":"Karasek M, Winczyk K. Melatonin in humans. J physiol pharmacology: official J pol physiological Soc. 2006;57(Suppl 5):19\u201339.","journal-title":"J Physiol Pharmacology: Official J Pol Physiological Soc"},{"key":"4526_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/biom13060943","author":"JA Boutin","year":"2023","unstructured":"Boutin JA, Kennaway DJ, Jockers R. Melatonin: facts, extrapolations and clinical trials. Biomolecules. 2023. https:\/\/doi.org\/10.3390\/biom13060943.","journal-title":"Biomolecules"},{"key":"4526_CR64","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/cia.S361519","volume":"18","author":"C Tuft","year":"2023","unstructured":"Tuft C, Matar E, Menczel Schrire Z, Grunstein RR, Yee BJ, Hoyos CM. Current insights into the risks of using melatonin as a treatment for sleep disorders in older adults. Clin Interv Aging. 2023;18:49\u201359. https:\/\/doi.org\/10.2147\/cia.S361519.","journal-title":"Clin Interv Aging"},{"issue":"2","key":"4526_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.117.241422","volume":"362","author":"CT Beuckmann","year":"2017","unstructured":"Beuckmann CT, Suzuki M, Ueno T, Nagaoka K, Arai T, Higashiyama H. In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017;362(2):287\u201395. https:\/\/doi.org\/10.1124\/jpet.117.241422.","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"4526_CR66","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","volume":"53","author":"CD Cox","year":"2010","unstructured":"Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, et al. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem. 2010;53(14):5320\u201332. https:\/\/doi.org\/10.1021\/jm100541c.","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"4526_CR67","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3109\/01677063.2011.566953","volume":"25","author":"CJ Winrow","year":"2011","unstructured":"Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, et al. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet. 2011;25(1\u20132):52\u201361. https:\/\/doi.org\/10.3109\/01677063.2011.566953.","journal-title":"J Neurogenet"},{"issue":"3","key":"4526_CR68","doi-asserted-by":"publisher","DOI":"10.52965\/001c.37400","volume":"10","author":"CL Robinson","year":"2022","unstructured":"Robinson CL, Supra R, Downs E, Kataria S, Parker K, Kaye AD, et al. Daridorexant for the treatment of insomnia. Health Psychol Res. 2022;10(3):37400. https:\/\/doi.org\/10.52965\/001c.37400.","journal-title":"Health Psychol Res"},{"key":"4526_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s44323-025-00025-5","author":"SM Ragsdale","year":"2025","unstructured":"Ragsdale SM, Radovich JM, Coiduras II, McCall WV, Grant SC, Lee C, et al. Dual orexin receptor antagonists as promising therapeutics for Alzheimer\u2019s disease. Npj Biol Timing Sleep. 2025. https:\/\/doi.org\/10.1038\/s44323-025-00025-5.","journal-title":"Npj Biol Timing Sleep"},{"issue":"1","key":"4526_CR70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/ana.26641","volume":"94","author":"BP Lucey","year":"2023","unstructured":"Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, et al. Suvorexant acutely decreases Tau phosphorylation and A\u03b2 in the human CNS. Ann Neurol. 2023;94(1):27\u201340. https:\/\/doi.org\/10.1002\/ana.26641.","journal-title":"Ann Neurol"},{"issue":"5","key":"4526_CR71","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.conb.2013.02.019","volume":"23","author":"MC Chen","year":"2013","unstructured":"Chen MC, Yu H, Huang ZL, Lu J. Rapid eye movement sleep behavior disorder. Curr Opin Neurobiol. 2013;23(5):793\u20138. https:\/\/doi.org\/10.1016\/j.conb.2013.02.019.","journal-title":"Curr Opin Neurobiol"},{"key":"4526_CR72","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1093\/brain\/awm056","volume":"130","author":"BF Boeve","year":"2007","unstructured":"Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson DW, Parisi JE, et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain. 2007;130:2770\u201388. https:\/\/doi.org\/10.1093\/brain\/awm056.","journal-title":"Brain"},{"key":"4526_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2022.113976","volume":"350","author":"AD Mizrahi-Kliger","year":"2022","unstructured":"Mizrahi-Kliger AD, Feldmann LK, K\u00fchn AA, Bergman H. Etiologies of insomnia in Parkinson\u2019s disease - lessons from human studies and animal models. Exp Neurol. 2022;350:113976. https:\/\/doi.org\/10.1016\/j.expneurol.2022.113976.","journal-title":"Exp Neurol"},{"issue":"2","key":"4526_CR74","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1007\/s12035-024-04400-4","volume":"62","author":"X Duan","year":"2025","unstructured":"Duan X, Liu H, Hu X, Yu Q, Kuang G, Liu L, et al. Insomnia in Parkinson\u2019s disease: causes, consequences, and therapeutic approaches. Mol Neurobiol. 2025;62(2):2292\u2013313. https:\/\/doi.org\/10.1007\/s12035-024-04400-4.","journal-title":"Mol Neurobiol"},{"key":"4526_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13081202","volume":"13","author":"S Thangaleela","year":"2023","unstructured":"Thangaleela S, Sivamaruthi BS, Kesika P, Mariappan S, Rashmi S, Choeisoongnern T, et al. Neurological insights into sleep disorders in Parkinson\u2019s disease. Brain Sci. 2023;13:8. https:\/\/doi.org\/10.3390\/brainsci13081202.","journal-title":"Brain Sci"},{"key":"4526_CR76","doi-asserted-by":"publisher","unstructured":"Davin A, Chabard\u00e8s S, Devergnas A, Benstaali C, Gutekunst CN, David O, et al. Excessive daytime sleepiness in a model of Parkinson\u2019s disease improved by low-frequency stimulation of the pedunculopontine nucleus. NPJ Parkinsons Dis. 2023;9(1:9). https:\/\/doi.org\/10.1038\/s41531-023-00455-7.","DOI":"10.1038\/s41531-023-00455-7"},{"issue":"24","key":"4526_CR77","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1111\/bph.15660","volume":"178","author":"YF Yang","year":"2021","unstructured":"Yang YF, Dong H, Shen Y, Li L, Lazarus M, Qu WM, et al. Mesencephalic dopamine neurons are essential for modafinil-induced arousal. Br J Pharmacol. 2021;178(24):4808\u201325. https:\/\/doi.org\/10.1111\/bph.15660.","journal-title":"Br J Pharmacol"},{"key":"4526_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz031","author":"X Yu","year":"2019","unstructured":"Yu X, Ma Y, Harding EC, Yustos R, Vyssotski AL, Franks NP, et al. Genetic lesioning of histamine neurons increases sleep-wake fragmentation and reveals their contribution to modafinil-induced wakefulness. Sleep. 2019. https:\/\/doi.org\/10.1093\/sleep\/zsz031.","journal-title":"Sleep"},{"issue":"3","key":"4526_CR79","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ana.25423","volume":"85","author":"MJ Thorpy","year":"2019","unstructured":"Thorpy MJ, Shapiro C, Mayer G, Corser BC, Emsellem H, Plazzi G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359\u201370. https:\/\/doi.org\/10.1002\/ana.25423.","journal-title":"Ann Neurol"}],"updated-by":[{"DOI":"10.1186\/s12883-026-04678-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000}}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04526-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04526-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:35:33Z","timestamp":1770791733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-025-04526-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4526"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04526-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"1 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: the authors reported a typesetting error of the authorship. Hong Zhou, Jun Hu and Xinzheng Wang are co-corresponding authors instead of Hong Zhou only.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12883-026-04678-y","URL":"https:\/\/doi.org\/10.1186\/s12883-026-04678-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"504"}}